HIGHLIGHTS
- who: March and colleagues from the Dalian Medical University, China have published the article: A mass balance study of [ C] SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans, in the Journal: (JOURNAL)
- what: In cancer treatment, the target of blocking cell division is a very important research goal. In this study, data are collected through the XCalibur and Laura systems. The main reason was that the radioactivity in plasma was too low, and the signals of metabolites could not be distinguished from the background signal. This study shows that after a single . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.